Pharmacokinetic-pharmacodynamic comparison of ceftriaxone regimens in acute cholangitis.
Acute Disease
/ therapy
Aged
Aged, 80 and over
Anti-Bacterial Agents
/ pharmacology
Bacteria
/ drug effects
Bacterial Infections
/ diagnosis
C-Reactive Protein
/ analysis
Ceftriaxone
/ pharmacology
Cholangitis
/ diagnosis
Dose-Response Relationship, Drug
Drainage
/ methods
Drug Administration Schedule
Endoscopy, Digestive System
Female
Humans
Leukocyte Count
Male
Microbial Sensitivity Tests
Middle Aged
Prognosis
Retrospective Studies
Severity of Illness Index
Time Factors
Treatment Outcome
Acute cholangitis
Ceftriaxone
MIC
Pharmacokinetic–pharmacodynamics
Journal
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
ISSN: 1437-7780
Titre abrégé: J Infect Chemother
Pays: Netherlands
ID NLM: 9608375
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
30
01
2019
revised:
27
03
2019
accepted:
08
04
2019
pubmed:
28
5
2019
medline:
28
1
2020
entrez:
28
5
2019
Statut:
ppublish
Résumé
The most important factors determining the prognosis of patients with acute cholangitis (AC) are prompt biliary drainage and appropriate choice of antibiotics. This study was performed to evaluate whether dividing the number of doses based on the PK-PD theory contributes to better clinical outcome in the management of acute cholangitis. We measured ceftriaxone levels in blood and bile in 21 cases diagnosed with moderate-to-severe AC. Eleven cases were administered 2 g of ceftriaxone once-daily (group A) and 10 cases were given 1 g of ceftriaxone twice-daily (group B). The theoretical effect of ceftriaxone was evaluated by pharmacokinetic-pharmacodynamic (PK-PD) parameters. Clinical efficacy was evaluated by body temperature, white blood cell count and serum levels of C-reactive protein. Minimum level of ceftriaxone in serum (in mg/L) in groups A and B at 24 h after the first dose was 9.1 and 9.2, whereas that in bile was 2.9 and 2.5, respectively. The minimum inhibitory concentration (MIC) of ceftriaxone for all isolated bacteria was below the minimum serum and biliary concentration of ceftriaxone 24 h after the first administration (except for Enterococcus species). The MIC for isolated bacterial strains was <16 mg/L, which is the PK-PD breakpoint for ceftriaxone at 2 g/day. Both regimens showed clinical efficacy and did not contradict the effect predicted based on PK-PD.
Identifiants
pubmed: 31130393
pii: S1341-321X(19)30098-4
doi: 10.1016/j.jiac.2019.04.006
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Ceftriaxone
75J73V1629
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
780-785Informations de copyright
Copyright © 2019 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.